Gamma Biosciences, a global life sciences company in the advanced therapy market, has agreed to make a controlling investment in Mirus Bio, a developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery based in Madison, WI.   The transaction will support Mirus’ plans to expand GMP production and commercialization of its flagship product TransIT VirusGEN for large scale manufacturing of AAV and LV-based viral vectors for gene therapy, as well as further ...